Medigen Vaccine Biologics (6547) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medigen Vaccine Biologics (6547) has a cash flow conversion efficiency ratio of 0.029x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$101.08 Million ≈ $3.18 Million USD) by net assets (NT$3.48 Billion ≈ $109.62 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Medigen Vaccine Biologics liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Medigen Vaccine Biologics - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Medigen Vaccine Biologics's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Medigen Vaccine Biologics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medigen Vaccine Biologics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EQV Ventures Acquisition Corp. II
NYSE:EVAC
|
0.000x |
|
VST Industries Limited
NSE:VSTIND
|
0.048x |
|
Icon Offshore Bhd
KLSE:5255
|
0.083x |
|
Zhuhai Comleader Information Science & Technology Co. Ltd. A
SHG:688175
|
N/A |
|
Boiron SA
PA:BOI
|
0.070x |
|
Aprogen KIC Inc
KO:007460
|
-0.041x |
|
Baida Group Co Ltd
SHG:600865
|
0.003x |
|
BECE Legend Group Co Ltd
SHE:000803
|
0.107x |
Annual Cash Flow Conversion Efficiency for Medigen Vaccine Biologics (2012–2025)
The table below shows the annual cash flow conversion efficiency of Medigen Vaccine Biologics from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Medigen Vaccine Biologics.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$3.48 Billion ≈ $109.62 Million |
NT$-49.09 Million ≈ $-1.55 Million |
-0.014x | -233.28% |
| 2024-12-31 | NT$3.85 Billion ≈ $121.30 Million |
NT$40.75 Million ≈ $1.28 Million |
0.011x | +108.52% |
| 2023-12-31 | NT$3.85 Billion ≈ $121.19 Million |
NT$-477.75 Million ≈ $-15.05 Million |
-0.124x | +43.27% |
| 2022-12-31 | NT$5.03 Billion ≈ $158.44 Million |
NT$-1.10 Billion ≈ $-34.69 Million |
-0.219x | -276.53% |
| 2021-12-31 | NT$4.68 Billion ≈ $147.32 Million |
NT$579.89 Million ≈ $18.27 Million |
0.124x | +166.03% |
| 2020-12-31 | NT$3.14 Billion ≈ $98.97 Million |
NT$-589.97 Million ≈ $-18.59 Million |
-0.188x | +44.52% |
| 2019-12-31 | NT$1.37 Billion ≈ $43.06 Million |
NT$-462.65 Million ≈ $-14.58 Million |
-0.338x | -53.14% |
| 2018-12-31 | NT$1.61 Billion ≈ $50.79 Million |
NT$-356.33 Million ≈ $-11.23 Million |
-0.221x | -54.92% |
| 2017-12-31 | NT$1.52 Billion ≈ $47.92 Million |
NT$-217.03 Million ≈ $-6.84 Million |
-0.143x | -28.34% |
| 2016-12-31 | NT$1.47 Billion ≈ $46.30 Million |
NT$-163.37 Million ≈ $-5.15 Million |
-0.111x | -169.10% |
| 2015-12-31 | NT$1.34 Billion ≈ $42.35 Million |
NT$216.26 Million ≈ $6.81 Million |
0.161x | +133.76% |
| 2014-12-31 | NT$1.08 Billion ≈ $33.99 Million |
NT$-513.98 Million ≈ $-16.19 Million |
-0.476x | -201.54% |
| 2013-12-31 | NT$457.94 Million ≈ $14.43 Million |
NT$-72.36 Million ≈ $-2.28 Million |
-0.158x | -269.62% |
| 2012-12-31 | NT$128.00 Million ≈ $4.03 Million |
NT$-5.47 Million ≈ $-172.40K |
-0.043x | -- |
About Medigen Vaccine Biologics
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more